Phase III randomized trial of amifostine as a radioprotector in head and neck cancer

Journal of Clinical Oncology

Volumn 18, Issue 19, 2000, Pages 3339-3345

  Brizel, David M ^a   Wasserman, Todd H ^a   Henke, Michael ^a   Strnad, Vratislav ^a   Rudat, Volkar ^a   Monnier, Alain ^a   Eschwege, Francois ^a   Zhang, Jay ^a   Russell, Lesley ^a   Oster, Wolfgang ^a   Sauer, Rolf ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE;

ADULT; AGED; ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION PROTECTION; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA; XEROSTOMIA;

EID: 0034305965     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.19.3339     Document Type: Article

References (27)

1. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer
2. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients
3. The role of WR-2721 in radiotherapy and/or chemotherapy
4. Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse
5. Biodistribution of the radioprotective drug S-labeled 3-amino-2-hydroxy-propyl phosphorothioate (WR77913)
6. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer
7. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer
8. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction
9. Patient benefit questionnaire (PBQ) for xerostomia: Development and validation report
10. P value adjustments for multiple tests in multivariate binomial models
11. Improved methodology for analyzing local and distant recurrence
12. Analysis of the probability and risk of cause-specific failure
13. Nonparametric estimation from incomplete observations
14. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: First report of a prospective randomized trial
15. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
16. The randomization and stratification of patients to clinical trials
17. Minimization: A new method of assigning patients to treatment and control groups
18. Oral mucosal status and major salivary gland function
19. Major salivary gland function in patients with radiation-induced xerostomia: Flow rates and sialochemistry
20. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy
21. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves local regional control in the radiotherapy of advanced head and neck cancers: Results of EORTC 22851 randomized trial
22. Hyperfractionated irradiation with and without concurrent chemotherapy for locally advanced head and neck cancer
23. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck
24. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability: Copolymer 1 Multiple Sclerosis Study Group
25. Recursive partitioning analysis of 2105 patients treated in Radiation Therapy Oncology Group Studies of head and neck cancer
26. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: Results of RTOG 88- 09